| 產(chǎn)品名稱(chēng) |
Pseudomonas aeruginosa (Schroeter) Migula |
| 商品貨號(hào) |
B161482 |
| Reports |
Upon your purchase of this product, you will receive a report containing MIC values, a susceptibility profile, and the DNA sequence information for predicted annotated antibiotic resistance genes and 16S rRNA genes. This report will be provided in multiple formats (.pdf, .txt, .xls, .zip). |
| Deposited As |
Pseudomonas aeruginosa |
| Strain Designations |
1109196 |
| Application |
Drug discovery and development
Development of molecular-based detection assays
Development of updated sterility protocols |
| Isolation |
Endotrachial aspirate |
| Isolation Date |
2014 |
| Geographic Source |
Colombia |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen |
| Storage Conditions |
-80°C or colder |
| Preceptrol® |
no |
| Annotated Genes |
aadA
amrA
amrB
ANT2-Ia
APH(3')-IIb
catB7
KPC-2
macB
mexA
mexB
mexC
mexD
mexE
mexF
mexH
mexI
mexK
mexN
mexP
mexQ
mexV
mexW
msbA
muxB
muxC
oprM
OXA-2
OXA-50
PDC-2
|
| Type Strain |
no |
| MIC Range |
Susceptible
Colistin: ≤2 µg/mL
Levofloxacin: ≥8 µg/mL
Resistant
Amikacin: ≥64 µg/mL
Aztreonam: ≥32 µg/mL
Cefepime: ≥32 µg/mL
Ceftazidime: ≥32 µg/mL
Ciprofloxacin: ≥4 µg/mL
Doripenem: ≥8 µg/mL
Imipenem: ≥8 µg/mL
Meropenem: ≥8 µg/mL
Piperacillin-tazobactam: ≥128/4 µg/mL
|
| Comments |
This strain is part of the Global Priority Superbugs collection. It is an extensively characterized antimicrobial-resistant clinical isolate with validated genotypic and phenotypic activity against a variety of drug classes. This strain is provided with geographic source information; an NGS-assembled whole genome sequence, including annotated antibiotic resistance and rRNA genes; and an expanded level of susceptibility data with MIC test results.
Minimum inhibitory concentration (MIC) ranges for resistant, intermediate, and susceptible are based on criteria within the Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition.
Predicted antimicrobial resistance gene sequence data are provided for informational purposes only and are based on open reading frames (ORFs) identified and annotated from contigs produced during next-generation sequencing (NGS). ATCC does not warrant that the entire predicted antimicrobial resistance gene is present within the sequence prepared for lot-specific reports. Likewise, the information provided merely indicates that some portion of the sequence (whole or in part) is present based on analytical base pair alignment with known gene sequences. |
| Medium |
ATCC® Medium 18: Trypticase Soy Agar/Broth
|
| Growth Conditions |
Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor |
International Health Management Associates (IHMA), Inc. |
| Special Collection |
Global Priority Superbugs |
| Chain of Custody |
ATCC <-- International Health Management Associates (IHMA), Inc. |
| Patient Age |
51 |
| Patient Gender |
Male |
| References |
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Wayne, PA. M100S, 2016.
|
